BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15367407)

  • 1. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
    Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended rituximab therapy in Waldenström's macroglobulinemia.
    Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
    Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
    Treon SP; Hunter Z; Barnagan AR
    Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
    Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
    Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
    Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
    J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
    Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
    Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
    Ito K; Kawasaki T; Hirano K; Sekiguchi N
    Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
    Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
    Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
    Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
    Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
    Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options in Waldenstrom's macroglobulinemia.
    Björkholm M
    Clin Lymphoma; 2004 Dec; 5(3):155-62. PubMed ID: 15636690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
    Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
    Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
    Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
    Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
    Menke MN; Feke GT; McMeel JW; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):100-3. PubMed ID: 19362987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.